Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases

LAB eN² will involve institutions including Harvard University, Mass General Brigham, and Beth Israel Deaconess Medical Center Focus of the collaboration is to accelerate the translation of academic ideas to therapeutic product candidates in the cardiometabolic space CAMBRIDGE, Mass. and…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.